Q1 2017: Probi continues on its successful growth path
Highlights and significant events during the first quarter · Significant increase in sales and earnings driven by Nutraceutix acquisition and organic growth · Market launch of patented and clinically documented Probi SelectTM product range in North America · Start of strategic initiatives to increase production capacity and to design a new Group enterprise system (ERP) Financial overview MSEK Q1 Q1 Full-year 2017 2016 2016Net sales 187.4 87.0 443.5Net sales growth, local